These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 7511575

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.
    Uchiyama-Kokubu N, Watanabe T, Cohen D.
    Jpn J Cancer Res; 2001 Oct; 92(10):1116-26. PubMed ID: 11676863
    [Abstract] [Full Text] [Related]

  • 43. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
    Theyer G, Schirmböck M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G.
    J Urol; 1993 Nov; 150(5 Pt 1):1544-7. PubMed ID: 8105110
    [Abstract] [Full Text] [Related]

  • 44. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
    Werlenius O, Aurelius J, Hallner A, Akhiani AA, Simpanen M, Martner A, Andersson PO, Hellstrand K, Thorén FB.
    Oncotarget; 2016 May 31; 7(22):32046-53. PubMed ID: 27097113
    [Abstract] [Full Text] [Related]

  • 45. Effect of in vitro cyclosporin. A treatment on human natural and antibody-dependent cell-mediated cytotoxicity.
    Shao-Hsien C, Lang I, Gunn H, Lydyard P.
    Transplantation; 1983 Feb 31; 35(2):127-9. PubMed ID: 6829073
    [Abstract] [Full Text] [Related]

  • 46. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein.
    Tsuji A, Tamai I, Sakata A, Tenda Y, Terasaki T.
    Biochem Pharmacol; 1993 Sep 14; 46(6):1096-9. PubMed ID: 8105783
    [Abstract] [Full Text] [Related]

  • 47. Expression and function of multidrug resistance P-glycoprotein in a cultured natural killer cell-rich population revealed by MRK16 monoclonal antibody and AHC-52.
    Kobayashi Y, Yamashiro T, Nagatake H, Yamamoto T, Watanabe N, Tanaka H, Shigenobu K, Tsuruo T.
    Biochem Pharmacol; 1994 Oct 18; 48(8):1641-6. PubMed ID: 7980629
    [Abstract] [Full Text] [Related]

  • 48. Influence of systemic chemotherapy on anti-P-glycoprotein antibody-dependent cell-mediated cytotoxicity in patients with small cell lung cancer.
    Nabioullin R, Yanagawa H, Haku T, Hiramatsu K, Yano S, Hanibuchi M, Pai K, Tsuruo T, Sone S.
    Jpn J Clin Oncol; 1995 Aug 18; 25(4):124-30. PubMed ID: 7666588
    [Abstract] [Full Text] [Related]

  • 49. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia.
    Grey MR, Burgess R, Fisher A, Yin JA.
    Leuk Res; 1999 Jan 18; 23(1):29-35. PubMed ID: 9933132
    [Abstract] [Full Text] [Related]

  • 50. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma.
    Pilarski LM, Belch AR.
    Blood; 1994 Feb 01; 83(3):724-36. PubMed ID: 7507731
    [Abstract] [Full Text] [Related]

  • 51. Antibody-dependent cell-mediated cytotoxicity (ADCC) toward human O+ red cells coated with anti-D antibody: comparison between lymphocyte and monocyte ADCC activity.
    Sunada M, Suzuki S, Ota Z.
    Acta Med Okayama; 1985 Apr 01; 39(2):77-89. PubMed ID: 3923782
    [Abstract] [Full Text] [Related]

  • 52. Human monocyte antibody-dependent cell-mediated cytotoxicity to tumor cells.
    Shaw GM, Levy PC, LoBuglio AF.
    J Clin Invest; 1978 Dec 01; 62(6):1172-80. PubMed ID: 748372
    [Abstract] [Full Text] [Related]

  • 53. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents.
    Boesch D, Loor F.
    Anticancer Drugs; 1994 Apr 01; 5(2):229-38. PubMed ID: 7914109
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
    Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J.
    Cancer Immunol Res; 2015 Oct 01; 3(10):1148-1157. PubMed ID: 26014098
    [Abstract] [Full Text] [Related]

  • 56. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.
    Loor F, Tiberghien F, Wenandy T, Didier A, Traber R.
    J Med Chem; 2002 Oct 10; 45(21):4598-612. PubMed ID: 12361387
    [Abstract] [Full Text] [Related]

  • 57. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
    Jonsson B, Nilsson K, Nygren P, Larsson R.
    Anticancer Drugs; 1992 Dec 10; 3(6):641-6. PubMed ID: 1363199
    [Abstract] [Full Text] [Related]

  • 58. Verapamil and cyclosporin A sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes in the cytoplasmic free Ca2+ concentration.
    Nygren P, Larsson R.
    Biosci Rep; 1990 Apr 10; 10(2):231-7. PubMed ID: 1972632
    [Abstract] [Full Text] [Related]

  • 59. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
    Lehne G, Rugstad HE.
    Br J Cancer; 1998 Sep 10; 78(5):593-600. PubMed ID: 9744497
    [Abstract] [Full Text] [Related]

  • 60. Evaluation of multiple drug resistance in human bladder cancer cell lines.
    Shinohara N, Liebert M, Wedemeyer G, Chang JH, Grossman HB.
    J Urol; 1993 Aug 10; 150(2 Pt 1):505-9. PubMed ID: 8100862
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.